Brian Park, PharmD

Drug Information Specialist https://www.medicalbag.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

News

Bivalent RSV Maternal Vaccine Candidate Gets FDA’s Priority Review

Brian Park, PharmD

March 16, 2023

The BLA is supported by data from a phase 3 trial which included approximately 7400 pregnant individuals.

News

Molnupiravir Misses Endpoint in COVID-19 Prevention Study

Brian Park, PharmD

March 16, 2023

The MOVe-AHEAD study enrolled over 1500 participants 18 years of age and older who resided in the same household with someone who tested positive for SARS-CoV-2.

News

FDA to Review Novel Corrective Eye Drop Candidate for Presbyopia

Brian Park, PharmD

March 16, 2023

CSF-1 is a preservative-free solution that contains a combination of low-dose pilocarpine hydrochloride 0.4% and multifaceted vehicle.

News

Myostatin-Targeting Biologic Fast Tracked for Spinal Muscular Atrophy

Brian Park, PharmD

March 16, 2023

The Company is currently evaluating the efficacy and safety of taldefgrobep alfa in patients with SMA in the phase 3 RESILIENT study.

News

Pozelimab Gets Priority Review for CHAPLE, a Rare Hereditary Immune Disease

Brian Park, PharmD

March 16, 2023

CHAPLE disease is a rare genetic disorder caused by mutations in the CD55 gene.

News

At-Home Combination Test for COVID-19, Flu Gets Emergency Use Authorization

Brian Park, PharmD

March 16, 2023

The Lucira COVID-19 & Flu Home test is a single-use, nucleic acid amplification test intended for individuals with signs and symptoms consistent with a respiratory tract infection.

News

Prostate Cancer Treatment Pluvicto Currently in Shortage

Brian Park, PharmD

March 16, 2023

Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.

News

Nivolumab sBLA Accepted for Patients With Completely Resected Stage IIB, IIC Melanoma

Brian Park, PharmD

March 16, 2023

The sBLA is supported by data from the phase 3 CheckMate -76K trial which included 790 patients after complete resection of stage IIB or IIC melanoma.